Rimidi, Inc.(formerly known as Rimidi Diabetes), an Atlanta-based digital health startup that provides software and clinical analytics for chronic disease management, announced it has raised $6.575 million in Series A-1 financing, which includes a strategic investment by Eli Lilly and Company, an investment from Turner Investments, and participation from existing investors Cox Enterprises, Village Capital, The Jump Fund, and JAMB Global. The company plans to use the funding round to fuel growth and accelerate its market penetration.
In the US, we spend $345 billion each year on diabetes-related costs, a large percentage of the $727 billion that goes to diabetes globally. This cost is born by those living with diabetes, taxpayers, and employers plus the lost productivity related to poorly-controlled diabetes.
Founded in 2012, Rimidi’s platform helps clinicians personalize care for individuals by leveraging both patient generated data, clinical information, and the latest practice guidelines. The platform enables clinicians to identify individuals who may benefit from specific therapeutic approaches. The platform integrates with leading electronic medical records (EMR) systems, providing a seamless workflow experience for clinicians at the point of care.
Rimidi core offerings include:
– Rimidi | Diabetes empowers patients and providers to identify gaps in diabetes management as well as the necessary steps to close those gaps, meet patient glucose targets and create a more efficient cycle of care.
– Rimidi | Heart Failure enables efficient monitoring across a population of patients with heart failure, decreasing the likelihood of avoidable admissions and exacerbations
“We are excited to close this successful round, and focus on the road ahead,” stated Rimidi CEO Josh Claman. “Helping healthcare providers transition to more proactive and data-driven care delivery models is proving again and again to improve health outcomes and reduce the avoidable complications of these diseases. This round will allow us to push more aggressively into the market and accelerate our expansion into other cardio-metabolic comorbidities.”
